Sol-Gel Technologies (SLGL) Cash & Equivalents (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Cash & Equivalents of $10.1 million for Q1 2026, down 39.99% year-over-year from $16.9 million in Q1 2025, and down 8.13% quarter-over-quarter from $11.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Cash & Equivalents (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Cash & Equivalents data on file, last reported at $10.1 million in Q1 2026.
- Cash & Equivalents for Q1 2026 came in at $10.1 million, down 39.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.1 million (down 39.99% YoY), and the FY2025 annual result was $11.0 million, down 43.39% from the prior year.
- Cash & Equivalents fell to $10.1 million in Q1 2026 per SLGL's latest filing, from $11.0 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $21.3 million in Q1 2022 and troughed at $5.8 million in Q2 2022.
- A 5-year average of $11.9 million and a median of $11.2 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 80.39% in 2022, then soared 170.91% in 2023.
- A 5-year view of Cash & Equivalents shows it stood at $12.4 million in 2022, then plunged by 39.64% to $7.5 million in 2023, then surged by 159.4% to $19.5 million in 2024, then plunged by 43.39% to $11.0 million in 2025, then decreased by 8.13% to $10.1 million in 2026.
- Business Quant data shows SLGL's Cash & Equivalents at $10.1 million in Q1 2026, $11.0 million in Q4 2025, and $6.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 1.91 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.15 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.49 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 558.94 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.14 Mn |
| Dec 31, 2025 | 11.03 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 10.22 Mn |
| Mar 31, 2025 | 16.89 Mn |
| Dec 31, 2024 | 19.49 Mn |
| Sep 30, 2024 | 13.42 Mn |
| Jun 30, 2024 | 11.55 Mn |
| Mar 31, 2024 | 11.21 Mn |
| Dec 31, 2023 | 7.51 Mn |
| Sep 30, 2023 | 14.14 Mn |
| Jun 30, 2023 | 15.62 Mn |
| Mar 31, 2023 | 6.81 Mn |
| Dec 31, 2022 | 12.45 Mn |
| Sep 30, 2022 | 8.50 Mn |
| Jun 30, 2022 | 5.77 Mn |
| Mar 31, 2022 | 21.25 Mn |
| Dec 31, 2021 | 20.09 Mn |
| Sep 30, 2021 | 43.35 Mn |
| Jun 30, 2021 | 11.15 Mn |